Hospital
Concord Hospital-Franklin
Concord Hospital-Franklin was paid $2.72M by Medicaid between May 2021 and Nov 2024, across 84 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoCONCORD HOSPITAL-FRANKLIN
FRANKLIN, NH 03235
FRANKLIN, NH 03235
33aNPI1114005535assigned 11/02/2006
33bProvider typeCritical Access Hospital
28Total paid$2.72M
24GClaims41,734
24DCodes billed84
24AFirst – last monthMay 2021 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in New Hampshire
Rank by total paid#6 of 9
Median peer was paid$5.24M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 22,636 | $1.73M | |
| 2022 | 10,851 | $742K | |
| 2023 | 4,906 | $139K | |
| 2024incomplete | 3,341 | $115K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 2,403 | 1,780 | $647K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 2,089 | 1,268 | $625K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 2,767 | 1,809 | $601K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 291 | 209 | $149K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 613 | 483 | $107K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 329 | 239 | $75K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 1,706 | 1,291 | $49K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 489 | 380 | $44K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 966 | 698 | $41K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 771 | 576 | $38K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 1,157 | 904 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 919 | 699 | $30K |
72 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 500 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 788 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 292 | $18K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 20 | $18K |
| J3490 | Unclassified drugs | <1% | 2,419 | $16K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 754 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 102 | $14K |
| 80050 | General health panel | <1% | 1,693 | $12K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 330 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 736 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 291 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 516 | $10K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 101 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 504 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 105 | $8K |
| 96376 | <1% | 133 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 173 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 253 | $6K |
| 84484 | <1% | 1,253 | $5K | |
| 80061 | Lipid panel | <1% | 289 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 1,924 | $3K |
| 83690 | <1% | 604 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,003 | $2K |
| 82947 | <1% | 323 | $2K | |
| 83880 | <1% | 108 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 119 | $2K |
| 87040 | <1% | 304 | $2K | |
| 97161 | <1% | 21 | $2K | |
| 83605 | <1% | 308 | $1K | |
| 83735 | <1% | 405 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 297 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 297 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 448 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 450 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 51 | $1K |
| 84703 | <1% | 222 | $1K | |
| 81001 | <1% | 785 | $1K | |
| 85610 | <1% | 557 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 148 | $1K |
| 81025 | <1% | 231 | $1K | |
| 87186 | <1% | 209 | $998.71 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 271 | $983.42 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 205 | $945.77 |
| 85379 | <1% | 139 | $939.35 | |
| 87077 | <1% | 205 | $936.93 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 50 | $879.35 |
| 74018 | <1% | 18 | $765.12 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,413 | $725.77 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 308 | $708.34 |
| 73610 | <1% | 15 | $600.83 | |
| 73630 | <1% | 13 | $585.51 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 44 | $528.52 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 52 | $410.41 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $360.59 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $360.59 |
| 81003 | <1% | 335 | $335.46 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 39 | $324.01 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 33 | $288.81 |
| 87807 | <1% | 25 | $267.66 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 93 | $250.91 |
| 87088 | <1% | 97 | $208.78 | |
| 87081 | <1% | 49 | $208.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 35 | $161.41 |
| 86140 | <1% | 32 | $150.34 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 32 | $141.84 |
| 82728 | <1% | 13 | $126.12 | |
| 36416 | <1% | 42 | $115.92 | |
| 80305 | <1% | 109 | $67.34 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 407 | $64.48 |
| 85652 | <1% | 26 | $55.74 | |
| 85027 | <1% | 16 | $5.91 | |
| A9270 | Non-covered item or service | 0% | 1,022 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSLOANE, SCOTT (CHIEF FINANCIAL OFFICER)
Parent organizationCONCORD HOSPITAL-FRANKLIN
| Provider | Location | Paid |
|---|---|---|
| Concord Hospital, INC. | Concord, NH | $28.77M |
| Concord Hospital-Laconia | Laconia, NH | $9.25M |
| Concord Hospital-Franklin | Franklin, NH | $7.28M |
| Concord Hospital, INC. | Concord, NH | $3.74M |
| Concord Hospital-Franklin | Franklin, NH | $3.61M |
| Concord Hospital-Laconia | Laconia, NH | $2.92M |
| Concord Hospital-Laconia | Laconia, NH | $2.53M |
| Concord Hospital, INC. | Concord, NH | $2.48M |
| Concord Hospital-Laconia | Laconia, NH | $109K |
| Concord Hospital-Laconia | Laconia, NH | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.